PEDIATRICS Vol. 106 No. 4 October 2000, pp. 677-683
Received Oct 21, 1999; accepted Jan 25, 2000.
,
,
From the * Greenwood Genetic Center, Greenwood, South Carolina;
Fullerton Genetics, Asheville, North Carolina; § Department of
Pediatrics, Medical University of South Carolina, Charleston, South
Carolina;
Department of Obstetrics and Gynecology, University of
South Carolina School of Medicine, Columbia, South Carolina; and
¶ Department of Epidemiology and Biostatistics, University of South
Carolina School of Public Health, Columbia, South Carolina.
Objectives. To conduct surveillance for neural tube defects (NTDs) in a high-risk region of the United States and to prevent occurrence and recurrence of NTDs through the periconceptional use of folic acid supplements.
Design. Active and passive methods were used for surveillance of NTD-affected pregnancies and births during a 6-year period (October 1992-September 1998). Individual genetic counseling was used to prevent NTD recurrences and a public awareness campaign was used to reduce NTD occurrences.
Setting. State of South Carolina.
Patients. All cases of spina bifida, anencephaly, and encephalocele identified among 278 122 live births and fetal deaths to South Carolina residents during 1992-1998 were included.
Main Outcome Measure. Changes in occurrence and recurrence rates during a 6-year period.
Results. Over the 6 years of surveillance, the prevalence rates for NTDs decreased from 1.89 to .95 cases per 1000 live births and fetal deaths. The prevalence decrease is explained primarily by a decrease in cases of spina bifida. Isolated NTDs accounted for 297/360 (82%) NTDs and 63/360 (18%) had at least 1 other structural anomaly. Females predominated among isolated NTDs but the sex distribution was equal among NTD cases with other anomalies. Prevalence rates for whites (1.48 cases per 1000 live births and fetal deaths) were higher than rates for blacks (.87 cases per 1000 live births and fetal deaths). There were no NTD recurrences in 113 subsequent pregnancies to mothers of infants with isolated NTDs who took periconceptional folic acid. The rate of periconceptional folic acid use among women of childbearing years increased from 8% to 35% during the 6-year project period.
Conclusion. The prevalence of NTDs in a high-risk region has declined coincident with the increased periconceptional use of folic acid supplements among women of childbearing age.neural tube defects, high-risk region, birth defects, folic acid, spina bifida, anencephaly, encephalocele. .
This article has been cited by other articles:
![]() |
P. A. Romitti Utility of Family History Reports of Major Birth Defects as a Public Health Strategy Pediatrics, September 1, 2007; 120(SUPPLEMENT_2): S71 - S77. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Mason, A. Dickstein, P. F. Jacques, P. Haggarty, J. Selhub, G. Dallal, and I. H. Rosenberg A Temporal Association between Folic Acid Fortification and an Increase in Colorectal Cancer Rates May Be Illuminating Important Biological Principles: A Hypothesis Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1325 - 1329. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Rowland, A. Correa, J. D. Cragan, and C. J. Alverson Are Encephaloceles Neural Tube Defects? Pediatrics, September 1, 2006; 118(3): 916 - 923. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tamura and M. F. Picciano Folate and human reproduction Am. J. Clinical Nutrition, May 1, 2006; 83(5): 993 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Bol, J. S. Collins, R. S. Kirby, and for the National Birth Defects Prevention Network Survival of Infants With Neural Tube Defects in the Presence of Folic Acid Fortification Pediatrics, March 1, 2006; 117(3): 803 - 813. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Brent and G. P. Oakley Jr Triumph and/or Tragedy: The Present Food and Drug Administration Program of Enriching Grains With Folic Acid Pediatrics, March 1, 2006; 117(3): 930 - 932. [Full Text] [PDF] |
||||
![]() |
Y.-I. Kim Will mandatory folic acid fortification prevent or promote cancer? Am. J. Clinical Nutrition, November 1, 2004; 80(5): 1123 - 1128. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thomas The Lemon Sign Radiology, July 1, 2003; 228(1): 206 - 207. [Full Text] [PDF] |
||||
![]() |
L. B. Bailey, G. C. Rampersaud, and G. P. A. Kauwell Folic Acid Supplements and Fortification Affect the Risk for Neural Tube Defects, Vascular Disease and Cancer: Evolving Science, J. Nutr., June 1, 2003; 133(6): 1961S - 1968. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Holden, J. S. Collins, J. F. Greene, S. Hinkle, A. F. Nave, J. M. Portillo, G. P. Page, and R. E. Stevenson Dietary Intake and Blood Folate Levels in Honduran Women of Childbearing Age J Child Neurol, May 1, 2002; 17(5): 341 - 345. [Abstract] [PDF] |
||||
![]() |
S Dastgiri, D H Stone, C Le-Ha, and W H Gilmour Prevalence and secular trend of congenital anomalies in Glasgow, UK Arch. Dis. Child., April 1, 2002; 86(4): 257 - 263. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Mills and L. England Food Fortification to Prevent Neural Tube Defects: Is It Working? JAMA, June 20, 2001; 285(23): 3022 - 3023. [Full Text] [PDF] |
||||